{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061121","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.174646+00:00","generated_at":"2026-06-08T09:48:27.290356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio Q3 net loss $49.9M ($1.16/share); goodwill impairment of $19.5M","bullets":["Revenue not reported; R&D expenses $26.2M vs $16.6M YoY; G&A $6.6M vs $6.4M.","Cash $183.3M at Sept 30 2023, down from $257.7M at Dec 31 2022; runway into H1 2025.","Initiated ADI-001 EXPAND cohort in post-CAR T LBCL; MCL enrollment continues.","Prioritizing ADI-270 for solid tumors; IND filing expected H1 2024; paused ADI-925.","Goodwill fully impaired by $19.5M following impairment test."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061121","json":"https://secwatch.observer/filing/0000950170-23-061121.json","markdown":"https://secwatch.observer/filing/0000950170-23-061121.md","text":"https://secwatch.observer/filing/0000950170-23-061121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/0000950170-23-061121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/acet-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:48:27.290356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34e93bf8ff122eee26bd66a2838f808ae1ca5dcd","claim":"Adicet Bio, Inc. reported the third quarter ended September 30, 2023 results: net income $49.9 million, EPS $1.16 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended September 30, 2023 was $49.9 million, or a net loss of $1.16 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/0000950170-23-061121-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$49.9 million"},{"label":"EPS","value":"$1.16 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}